Profile data is unavailable for this security.
About the company
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
- Revenue in DKK (TTM)4.94bn
- Net income in DKK555.00m
- Incorporated1961
- Employees2.83k
- LocationALK-Abello A/SBoege Alle 6-8HOERSHOLM 2970DenmarkDNK
- Phone+45 45747576
- Fax+45 45748690
- Websitehttps://www.alk.net/
More ▼
Mergers & acquisitions
| Acquired company | ALK B:CPH since announced | Transaction value |
|---|---|---|
| AllerQuest LLC-PRE-PEN | 51.09% | -- |
Data delayed at least 15 minutes, as of Jul 04 2024 16:10 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioGaia AB | 856.95m | 244.64m | 7.90bn | 211.00 | 33.54 | 5.74 | 30.31 | 9.22 | 3.68 | 3.68 | 12.88 | 21.47 | 0.5414 | -- | -- | 6,192,767.00 | 15.46 | 15.47 | 16.82 | 16.93 | 73.32 | 73.30 | 28.55 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| Calliditas Therapeutics AB | 863.90m | -345.83m | 8.07bn | 219.00 | -- | 91.84 | -- | 9.34 | -9.78 | -9.78 | 24.43 | 2.24 | 0.7541 | 3.16 | 8.97 | 6,723,169.00 | -30.19 | -26.46 | -38.05 | -30.27 | 95.01 | -- | -40.03 | -76.59 | 2.62 | -3.99 | 0.8943 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| Vimian Group AB | 2.50bn | 59.13m | 11.34bn | 1.10k | 172.66 | 2.57 | 36.40 | 4.54 | 0.1928 | 0.1928 | 8.09 | 12.97 | 0.3354 | 2.83 | 5.69 | 3,442,408.00 | 0.867 | -- | 1.01 | -- | 47.48 | -- | 2.59 | -- | 1.19 | 2.81 | 0.3729 | -- | 17.92 | -- | 245.95 | -- | -- | -- |
| Bonesupport Holding AB | 432.11m | 175.65m | 11.40bn | 121.00 | 65.07 | 30.56 | 62.43 | 26.38 | 4.05 | 4.05 | 9.96 | 8.61 | 1.19 | 0.657 | 6.36 | 6,245,276.00 | 48.22 | -9.08 | 61.41 | -11.28 | 92.01 | 90.25 | 40.65 | -11.65 | 2.42 | -- | 0.0282 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Bavarian Nordic A/S | 6.64bn | 984.37m | 13.67bn | 1.38k | 13.61 | 1.34 | 8.67 | 2.06 | 12.86 | 12.86 | 86.59 | 130.35 | 0.4956 | 1.74 | 9.32 | 4,816,359.00 | 7.35 | 1.21 | 8.92 | 1.48 | 60.90 | 53.72 | 14.82 | 4.06 | 1.03 | -- | 0.0427 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Camurus AB | 1.20bn | 296.84m | 22.64bn | 218.00 | 75.23 | 12.76 | 73.91 | 18.85 | 7.79 | 7.79 | 31.75 | 45.91 | 0.8265 | 1.14 | 6.65 | 8,557,742.00 | 20.43 | -1.13 | 23.79 | -1.41 | 93.17 | 90.05 | 24.71 | -1.63 | 7.39 | -- | 0.0086 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| ALK-Abello A/S | 4.94bn | 555.00m | 31.05bn | 2.83k | 61.51 | 7.23 | 36.45 | 6.28 | 2.49 | 2.49 | 21.93 | 21.19 | 0.752 | 1.29 | 5.81 | 1,749,646.00 | 8.45 | 3.50 | 10.36 | 4.37 | 63.25 | 60.66 | 11.23 | 5.07 | 1.23 | 50.27 | 0.0995 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| Orion Oyj | 9.10bn | 1.62bn | 43.57bn | 3.70k | 26.83 | 8.24 | 22.12 | 4.79 | 1.55 | 1.55 | 8.71 | 5.04 | 0.8866 | 1.57 | 6.01 | 336,013.20 | 15.73 | 19.47 | 21.38 | 24.16 | 55.10 | 59.38 | 17.74 | 20.71 | 1.00 | 74.43 | 0.2157 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| Swedish Orphan Biovitrum AB (publ) | 15.25bn | 1.41bn | 63.65bn | 1.75k | 44.04 | 2.58 | 17.39 | 4.17 | 6.19 | 6.19 | 69.32 | 105.59 | 0.3603 | 1.50 | 4.72 | 13,058,130.00 | 3.33 | 5.93 | 4.43 | 7.60 | 76.60 | 77.42 | 9.25 | 16.61 | 0.4994 | 3.56 | 0.3487 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
Data as of Jul 04 2024. Currency figures normalised to ALK-Abello A/S's reporting currency: Danish Krone DKK
17.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ATP Arbejdsmarkedets Till�gspensionas of 31 Dec 2023 | 11.23m | 5.54% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 4.87m | 2.40% |
| M&G Investment Management Ltd.as of 31 May 2024 | 4.19m | 2.07% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 3.46m | 1.71% |
| Danske Bank A/S (Investment Management)as of 31 May 2024 | 2.39m | 1.18% |
| Dimensional Fund Advisors LPas of 06 Jun 2024 | 2.14m | 1.06% |
| Nordea Investment Management AB (Denmark)as of 29 Feb 2024 | 1.92m | 0.95% |
| BlackRock Fund Advisorsas of 06 Jun 2024 | 1.90m | 0.94% |
| Artisan Partners LPas of 31 Mar 2024 | 1.69m | 0.83% |
| Invesco Asset Management Ltd.as of 29 Feb 2024 | 914.66k | 0.45% |
More ▼
Data from 31 Dec 2023 - 31 May 2024Source: FactSet Research Systems Inc.
